BET inhibition and depletion repress the expression of BRCA1 and RAD51

Slides:

Advertisements

Similar presentations

Anandamide inhibits the Wnt/β-catenin signalling pathway in human breast cancer MDA MB 231 cells Chiara Laezza, Alba D’Alessandro, Simona Paladino, Anna.

Advertisements

Effects of MAX reconstitution and of BRG1 depletion in lung cancer cells. Effects of MAX reconstitution and of BRG1 depletion in lung cancer cells. A,

Rab11-FIP3 silencing impairs T cell activation events.

Fig. 1. TP is highly expressed in myeloma.

BRD4 expression levels are associated with sensitivity to BET inhibition in NRAS‐mutant melanoma BRD4 expression levels are associated with sensitivity.

Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.

miR-133a positively regulated p53/p21 pathway.

Volume 15, Issue 6, Pages (June 2012)

Interferon (IFN)-Induced Protein 35 (IFI35), a Type I Interferon-Dependent Transcript, Upregulates Inflammatory Signaling Pathways by Activating Toll-Like.

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition by Jinsong Hu, Nana Dang, Eline Menu, Elke De Bryune, Dehui Xu, Ben Van.

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

A FOXO3a-BIM cascade mediates sensitivity to PARP and MEK inhibition

Fig. 2. Pharmacologic inhibition of ALK impairs STING activation.

Fig. 4. Bexarotene promotes PPARδ activation of target genes in mouse brain and muscle. Bexarotene promotes PPARδ activation of target genes in mouse brain.

Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.

Fig. 4. Functional annotation of VUS in EGFR.

JQ1 directly represses the promoter activities of BRCA1 and RAD51

Synergistic effect of S63845 with lapatinib, trastuzumab, or docetaxel

Fig. 1. PARPi and MEKi induce inverse adaptive responses.

Fig. 3. BET inhibition reduces homologous recombination.

Schedule-dependent interaction between anticancer treatments

BRD4 expression levels are associated with sensitivity to BET inhibition in NRAS‐mutant melanoma BRD4 expression levels are associated with sensitivity.

Fig. 6 pDCs infiltrate the skin of BLM-treated mice, and their depletion attenuates skin fibrosis. pDCs infiltrate the skin of BLM-treated mice, and their.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Fig. 2. Circulating VEGF in GCA patients up-regulates microvascular endothelial Jagged1. Circulating VEGF in GCA patients up-regulates microvascular endothelial.

Antiproliferative effects of JQ-EZ-05 on VHL−/− ccRCC are on-target

Fig. 2. Resistance to S63845-induced apoptosis through loss of BAK or elevated BCL-XL. Resistance to S63845-induced apoptosis through loss of BAK or elevated.

Fig. 1. Drug combination screen identifies BETi as acting synergistically with PARPi. Drug combination screen identifies BETi as acting synergistically.

Fig. 2 Fas controls IL-1RA–sEV secretion in murine MSCs.

Fig. 1 BX795 suppresses HSV-1 infection.

Fig. 1. PGBD5-expressing cells do not tolerate deficiency of nonhomologous end-joining DNA repair. PGBD5-expressing cells do not tolerate deficiency of.

Fig. 5. Nutlin-3 treatment rescues the proliferation and differentiation of NPCs in vitro. Nutlin-3 treatment rescues the proliferation and differentiation.

Fig. 2 Analysis of CLL lymph nodes.

Fig. 1. Bexarotene promotes PPARδ activation to ameliorate the neurotoxicity of mutant huntingtin. Bexarotene promotes PPARδ activation to ameliorate the.

Bexarotene is neuroprotective in mouse and human HD neurons in vitro

Fig. 2. Cellular response to FolamiRs in vitro.

Fig. 6 DMF inhibits NF-κB translocation upon infection.

Fig. 1 LB100 and LB102 specifically inhibit PP2A phosphatase activity and the growth of BCR-ABL+ cells. LB100 and LB102 specifically inhibit PP2A phosphatase.

Correlation of reovirus RNA/protein with proliferating tumor cells

Fig. 2. BET inhibition enhances PARPi-induced DNA damage.

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Knocking down Wnt3 increases the cells' response to trastuzumab and reduces cells' invasiveness. Knocking down Wnt3 increases the cells' response to trastuzumab.

Fig. 5. Mutant KRAS increases HR capacity and MEKi decreases HR capacity in RAS mutant cells, causing increased DNA damage. Mutant KRAS increases HR capacity.

Fig. 3. BET inhibition reduces homologous recombination.

MYC degradation screen identifies a compound that stabilizes MYC protein. MYC degradation screen identifies a compound that stabilizes MYC protein. (A)

BCL-3 regulates expression of stemness-associated Wnt targets.

CD151 effects on mammary cell morphology and adhesion.

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Fig. 1. DEL-1 is expressed by human and mouse osteoclasts.

CDCP1 is required for invadopodia formation and ECM degradation by human breast cancer cells. CDCP1 is required for invadopodia formation and ECM degradation.

CXCR4 expression levels of MDA-MB-231 cells at 48 hours posttransfection of CXCR4 siRNAs. CXCR4 expression levels of MDA-MB-231 cells at 48 hours posttransfection.

Effect of G9a on the expression of GSH synthesis enzymes.

RT-PCR and Western blot analysis of cIAP2 mRNA and protein expression in ovarian cancer cells. RT-PCR and Western blot analysis of cIAP2 mRNA and protein.

Pirh2 represses p73-dependent transactivation.

Effects of HDAC2 inactivation on the invasive potential of human gastric cancer cells. Effects of HDAC2 inactivation on the invasive potential of human.

Cell lines with aberrant expression of NRG1 are exquisitely sensitive to downregulation of ERBB3 signaling. Cell lines with aberrant expression of NRG1.

Fig. 1 Dcr-2 is required for Toll signaling in Drosophila S2 cells.

Fig. 5 C9orf72 knockdown disrupts autophagy induction.

Fig. 6 The C9ORF72/SMCR8 complex regulates ULK1.

Interaction of NHEJ and HR pathways in PCO cultures.

Expression and induction of HER2 and HPSE in 231BMBC cells.

PARP1 suppresses the transcription of PD-L1 in cancer cells.

Fig. 7. JQ1 represses the enhancer-promoter interaction of BRCA1.

Effect of dexamethasone on PCDGF/GP88 mRNA and protein expressions and effect of PCDGF/GP88 on dexamethasone-induced cell death. Effect of dexamethasone.

Fig. 3 Effects of ASO and eGLP1-ASO conjugates on gene expression and protein levels in vitro in cell lines and primary mouse islet cells. Effects of ASO.

Influence of minocycline on TGF-β1 expression and TGF-β1–induced NF-кB activation in ovarian cancer cells. Influence of minocycline on TGF-β1 expression.

JQ1 selectively ablates PAX3–FOXO1-driven transcription and BRD4 interaction. JQ1 selectively ablates PAX3–FOXO1-driven transcription and BRD4 interaction.

Fig. 2 hTERT induces expression of heat shock protein genes through HSF1 and interacts with Hsp70-1. hTERT induces expression of heat shock protein genes.

Presentation transcript:

Fig. 5. BET inhibition and depletion repress the expression of BRCA1 and RAD51. BET inhibition and depletion repress the expression of BRCA1 and RAD51. (A) Pathways overrepresented by JQ1 response genes (fold change, >2) in VCaP cells according to ConsensusPathDB analysis on the basis of gene ontology terms (left). Diagram depicts pathway interactions, grouped by pathways (right). Line thickness corresponds to the number of shared proteins between two pathways. Circle size corresponds to the number of JQ1 response genes in each pathway. The color intensity of circle indicates the P value for each pathway. miRNA, microRNA. (B) RNA expression of BRCA1, RAD51, and MYC in two independent microarray experiments in VCaP cells treated with DMSO or JQ1 (500 nM for 24 hours). (C) BRCA1 and RAD51 mRNA expression measured by real-time RT-PCR in MDA-MB-231 cells (left) and OVCAR10 cells (right) treated with 500 nM JQ1 for different time periods or with different concentrations of JQ1 for 72 hours. Error bars represent means ± SD. (D) BRCA1 and RAD51 expression assessed by Western blot in MDA-MB-231 cells treated with 500 nM JQ1 for different time periods (top) or with different concentrations of JQ1 for 72 hours (bottom). Tubulin and actin served as loading controls. (E) BRD2/3/4, BRCA1, and RAD51 mRNA expression in MDA-MB-231 cells treated with individual BRD2/3/4 siRNAs or with BRD2/3/4 siRNA pools. Error bars represent means ± SD. (F) BRD2/3/4, BRCA1, RAD51, and MYC expression measured by Western blot in cells treated with individual BRD2/3/4 siRNAs or with a BRD2/3/4 siRNA pool. Left: MDA-MB-231. Middle: OVCAR10. Right: VCaP. Actin served as a loading control. Lu Yang et al., Sci Transl Med 2017;9:eaal1645 Published by AAAS